1 results
Approved WMOCompleted
Primary Objective: • To determine the objective response rate (ORR) of tipifarnib in subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations with a VAF>=20% (High VAF population), as assessed by Independent Review…